Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-03-26 | Gregory J. Champion, age 66, has served on the Board of Directors of GFNB since April 2018 and on the Board of Managers of Upstate Agency, LLC, another Company subsidiary, since 2019. ... The Board has nominated Gregory J. Champion as a Class A Director. ... No committee memberships listed. ... No director compensation listed for 2020. |
| 2022-03-25 | Gregory J. Champion Mr. Champion, age 67, has been a Director of the Company since May 5, 2021 and a Director of GFNB since April 2018. Mr. Champion brings over 28 years of legal experience, including advising both privately-held and publicly-traded companies on corporate governance matters and serving as corporate secretary of both privately-held and publicly-traded companies. Mr. Champion has a B.A. from St. Lawrence University and a J.D. (summa cum laude) from Syracuse University College of Law. Mr. Champion serves as Executive Vice President, Legal, for Syncromune, Inc., a startup company seeking to develop intratumoral immunotherapy treatment for metastatic cancer patients. |
| 2023-09-13 | Mr. Champion, age 68, became a Director of the Company on May 5, 2021; ... 2022 Director Compensation Table ... Gregory J. Champion ... 2022 Director CompensationTotal $72,650 ... Committee Membership ... Gregory J. Champion Audit Committee X Compensation Committee X |
| 2024-04-25 | Mr. Champion, age 69, became a Director of the Company on May 5, 2021; he has been a Director of GFNB and SNB since April 2018 and April 2022, respectively. Mr. Champion brings more than 30 years of legal experience, including advising both privately held and publicly traded companies on corporate governance matters. Mr. Champion has a B.A. from St. Lawrence University and a J.D. (summa cum laude) from Syracuse University College of Law. Mr. Champion now serves as Chief Legal Officer for Syncromune, Inc., a startup company seeking to develop intra-tumoral immunotherapy treatment for metastatic cancer patients. |
Data sourced from SEC filings. Last updated: 2025-08-30